Jeff Yass’s Damora Therapeutics DMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$233K Sell
10,939
-1,070
-9% -$30.2K ﹤0.01% 11573
2026
Q2
$312K Buy
12,009
+2,239
+23% +$54.2K ﹤0.01% 10959
2026
Q1
$253K Buy
+9,770
New +$251K ﹤0.01% 11245
2025
Q3
– Sell
-13,602
Closed -$45.2K – 12951
2025
Q2
$45.2K Buy
13,602
+2,880
+27% +$8.52K ﹤0.01% 12143
2025
Q1
$33.2K Buy
+10,722
New +$50.5K ﹤0.01% 11981
2024
Q3
– Sell
-6,734
Closed -$79.8K – 12359
2024
Q2
$79.8K Buy
+6,734
New +$106K ﹤0.01% 11175
2024
Q1
– Sell
-1,101
Closed -$19.8K – 12595
2023
Q4
$19.8K Buy
+1,101
New +$16.9K ﹤0.01% 11977
2023
Q3
– Sell
-3,837
Closed -$242K – 12355
2023
Q2
$242K Buy
3,837
+1,316
+52% +$71.7K ﹤0.01% 9881
2023
Q1
$125K Buy
2,521
+1,012
+67% +$53.4K ﹤0.01% 11086
2022
Q4
$43.4K Sell
1,509
-600
-28% -$24.9K ﹤0.01% 11467
2022
Q3
$99K Buy
+2,109
New +$107K ﹤0.01% 11713
2022
Q1
– Sell
-639
Closed -$48K – 13364
2021
Q4
$48K Buy
+639
New +$50.2K ﹤0.01% 12570

Other funds holding DMRA

Jeff Yass's DMRA Position: Q3 2026 in Review

Jeff Yass reduced its Damora Therapeutics (DMRA) stake by 8.9% in Q3 2026, selling an estimated $30.2K and leaving 10,939 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #11573.

Jeff Yass first reported a position in DMRA in Q4 2021 and has held it in 12 quarters since. The position peaked at $312K in Q2 2026. 114 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • Jeff Yass held 10,939 shares of Damora Therapeutics worth $233K as of Q3 2026.
  • Jeff Yass sold 1,070 Damora Therapeutics shares in Q3 2026, an estimated $30.2K.
  • Damora Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #11573 holding.
  • Jeff Yass first reported a position in Damora Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Jeff Yass's Damora Therapeutics position peaked at $312K in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.